TAVI (Transcatheter Aortic Valve Implantation): Indications, Procedure, Recovery, and Cost in India

Q: What is TAVI (TAVR) and how does it work?

TAVI (Transcatheter Aortic Valve Implantation) is a minimally invasive percutaneous procedure to treat severe aortic stenosis. A collapsed artificial tissue valve is delivered on a catheter through a blood vessel in the groin (femoral artery) and expanded inside the diseased, calcified aortic valve, restoring normal blood flow without opening the chest or stopping the heart.

Q: Who is an ideal candidate for TAVI?

TAVI is recommended for patients with severe symptomatic aortic stenosis who are aged 75 years or older, or those of any age who have elevated surgical risk due to prior heart surgery, porcelain aorta, frailty, lung disease, or kidney impairment. Suitability requires confirmation of favorable femoral artery diameter and aortic root anatomy on a dedicated ECG-gated CT scan.

Q: How is TAVI different from open-heart surgical valve replacement (SAVR)?

SAVR requires a median sternotomy (cutting open the breastbone), stopping the heart with a heart-lung machine, surgical excision of the old valve, and a 6-to-8-week recovery. TAVI is performed through a pinhole in the groin, usually with mild conscious sedation, keeps the native valve pinned aside, and allows patients to walk the next day and return home in 2 to 4 days.

Q: Is TAVI painful or done under general anesthesia?

TAVI is generally painless once local numbing medication is applied to the groin. More than 80% of transfemoral TAVI cases are performed under conscious sedation (monitored anesthesia care), meaning you remain relaxed and breathing on your own without a general anesthesia breathing tube.

Q: Why do some patients need a permanent pacemaker after TAVI?

The heart's electrical conduction system (the AV node and bundle of His) runs directly underneath the aortic valve annulus. When the new stent frame expands against calcified leaflets, it can compress these electrical pathways, causing heart block. Approximately 5-15% of patients develop high-grade conduction delays requiring a permanent pacemaker.

Q: How long does a transcatheter aortic valve last?

Long-term data from landmark clinical trials indicate that TAVI tissue valves exhibit durability comparable to surgical bioprosthetic valves, with low rates of structural valve deterioration at 5 to 10 years. If a TAVI valve degenerates in the distant future, another catheter valve can often be placed inside it (TAVI-in-TAVI).

Q: What medications are required after TAVI?

Most patients without an existing indication for oral anticoagulation are prescribed Single Antiplatelet Therapy (lifelong low-dose aspirin). Routine lifelong warfarin is NOT required for TAVI valves. If you have atrial fibrillation, your cardiologist will maintain you on an oral anticoagulant alone.

Q: Why are prophylactic antibiotics required for dental visits after TAVI?

A transcatheter valve is a prosthetic device that can harbor bacteria circulating in the bloodstream during invasive dental procedures. Taking a single dose of prophylactic antibiotics (such as amoxicillin) 30 to 60 minutes before dental cleanings or extractions prevents infective endocarditis.

Q: How soon can I resume normal activities and driving?

Patients can walk within 12 to 24 hours and typically resume light daily activities within 1 to 2 weeks. Strenuous physical exertion and heavy lifting (>4-5 kg) should be avoided for 2 to 4 weeks to allow complete healing of the femoral puncture site. Driving is generally cleared after 2 to 4 weeks upon physician review.

Transcatheter Aortic Valve Implantation (TAVI), also known as Transcatheter Aortic Valve Replacement (TAVR), is a minimally invasive percutaneous procedure designed to replace a severely calcified, stenotic aortic valve without sternotomy (open-heart surgery) or cardiopulmonary bypass. This clinical guide outlines patient selection criteria, procedural pathways, prosthetic valve systems, recovery expectations, and treatment costs in India based on international cardiology guidelines.

Medically Reviewed ByDr. Mohd Ateequrrahman

TAVI (Transcatheter Aortic Valve Implantation): Indications, Procedure, Recovery, and Cost in India

Quick Clinical Summary

Medically Reviewed ByDr. Mohd Ateequrrahman

Medical illustration of TAVI (transcatheter aortic valve implantation)

Procedure Name
TAVI / TAVR (Transcatheter Aortic Valve Implantation / Replacement)
Primary Specialty
Interventional Cardiology (Structural Heart) & Cardiothoracic Surgery
Department
Multidisciplinary Structural Heart Team / Cardiac Cath Lab
Procedural Duration
1 to 2.5 hours (transfemoral approach)
Hospital Stay
2 to 4 days (typically 24 hours in the Cardiac Care Unit / CCU)

Recovery Timeline
Immediate ambulation within 12-24 hours; return to light routine in 1 to 2 weeks; full recovery in 4 weeks
Anesthesia
Local anesthesia with conscious sedation (monitored anesthesia care) in >80% of transfemoral cases; general anesthesia for complex or alternative access
Insurance & Scheme Coverage
Approved by many private insurance providers and corporate TPAs under medical necessity criteria; requires prior authorization. Selected public/central schemes (e.g., CGHS/EHS) offer reimbursement up to approved package caps.
Estimated Cost Range in India
Approximately Rs. 14,00,000 to Rs. 28,00,000 (varies based on domestic vs. imported valve systems and hospital tier)
Clinical Efficacy
Immediate hemodynamic relief; procedural success exceeds 95-97% in experienced structural heart centers with rapid reduction in transvalvular gradients

Free

Free Second Opinion

Get connected with a trusted doctor for an expert second opinion through our care team—at no cost.

Get Your Free Consultation

Clinical Signs and Symptoms of Severe Aortic Stenosis

Aortic stenosis (AS) typically exhibits a prolonged latent period during which progressive obstruction is offset by compensatory left ventricular hypertrophy. However, once the aortic valve area decreases below 1.0 cm² (or indexed valve area <0.6 cm²/m²) with mean transvalvular gradients >40 mmHg, hemodynamic decompensation occurs, precipitating the classic clinical triad:

Exertional Dyspnea (Heart Failure Symptoms): Shortness of breath during minor exertion, progressing to orthopnea and paroxysmal nocturnal dyspnea due to elevated left ventricular end-diastolic pressure and pulmonary venous congestion (average survival without intervention: ~2 years).
Angina Pectoris (Exertional Chest Pain): Substernal chest tightness precipitated by exertion, caused by severe myocardial supply-demand mismatch in hypertrophied myocardium, even in the absence of obstructive coronary disease (average survival without intervention: ~3 years).
Exertional Syncope or Presyncope: Sudden dizziness, lightheadedness, or loss of consciousness during exercise, resulting from fixed cardiac output in the setting of exercise-induced peripheral vasodilation or transient ventricular arrhythmias (average survival without intervention: ~3 years).
Fatigue and Exercise Intolerance: Profound reduction in stamina and functional capacity, often underreported by elderly patients who subconsciously adapt by restricting their daily activities.
Harsh Systolic Ejection Murmur: A crescendo-decrescendo systolic murmur loudest at the right second intercostal space, radiating to the carotid arteries, frequently accompanied by a diminished or delayed carotid pulse (pulsus parvus et tardus) and a soft second heart sound (absent or single A2).

Emergency Warning: The onset of syncope, angina, or resting breathlessness in patients with known severe aortic stenosis represents a medical emergency with high risk of sudden cardiac death. Urgent structural heart or cardiothoracic evaluation is imperative.

Etiology and Pathophysiology of Aortic Stenosis

Aortic stenosis is an active inflammatory and fibro-calcific process that leads to progressive leaflet stiffening, annular calcification, and narrowing of the aortic outflow tract. The primary underlying causes include:

Degenerative Calcific Aortic Stenosis (Senile AS): The most common etiology in individuals >65-70 years of age. Characterized by endothelial disruption, lipid infiltration, chronic inflammation, and osteogenic differentiation leading to massive nodular calcification at the leaflet bases.
Congenital Bicuspid Aortic Valve (BAV): Present in 1-2% of the general population. The presence of two unequal cusps creates altered shear stress, accelerating calcific degeneration 15 to 20 years earlier than in trileaflet valves (often presenting at age 45-65).
Rheumatic Heart Disease (RHD): Still prevalent in India and developing regions. Manifests as commissural fusion, leaflet retraction, and scarring, frequently co-existing with rheumatic mitral valve stenosis or regurgitation.
Secondary Accelerating Risk Factors: Chronic kidney disease (secondary hyperparathyroidism and disordered mineral metabolism accelerate valve calcification), severe dyslipidemia, and previous thoracic radiation therapy (radiation-induced valvulopathy).

Clinical Indications and Patient Selection for TAVI

Patient selection for TAVI versus Surgical Aortic Valve Replacement (SAVR) is established through shared clinical decision-making within the Heart Team, adhering to updated international guidelines (ACC/AHA and ESC/EACTS):

Age and Life Expectancy: TAVI is strongly recommended in patients aged ≥75-80 years or those with a life expectancy <10-20 years. In patients aged 65 to 75 years, both TAVI and SAVR are viable options, with the decision guided by anatomical factors, frailty, and patient preference. SAVR is typically favored in patients <65 years due to proven surgical bioprosthesis and mechanical valve longevity.

Surgical Risk Stratification: TAVI is the standard of care for patients categorized as prohibitive, high, or intermediate surgical risk, quantified by an STS-PROM (Society of Thoracic Surgeons Predicted Risk of Mortality) or EuroSCORE II score ≥4-8%.

Specific High-Risk Surgical Anatomies: Presence of a 'porcelain' (heavily calcified) ascending aorta, hostile chest environment resulting from prior median sternotomy (patent internal mammary coronary grafts crossing the midline), prior mediastinal chest radiation, or severe physical frailty.

Bioprosthetic Structural Valve Deterioration (Valve-in-Valve TAVI): Symptomatic failure, stenosis, or regurgitation of a previously implanted surgical tissue valve, avoiding high-risk redo sternotomy.

Clinical Contraindications and Deferral Criteria

Pure Severe Aortic Regurgitation: Absence of aortic leaflet calcification leaves the transcatheter stent frame without adequate anchoring substrate, predisposing to valve embolization (SAVR remains the first-line gold standard).

Active Endocarditis or Systemic Sepsis: Implantation of an endovascular prosthesis in an infected field is contraindicated.

Complex Multivessel or Multi-Valvular Disease: Severe concomitant mitral or tricuspid pathology, or complex coronary bifurcation disease requiring surgical revascularization (CABG), where combined open surgery addresses all pathologies in a single setting.

Inadequate Annular Dimensions or Coronary Obstruction Risk: Annulus size outside manufacturer specifications, or low coronary ostial takeoff (<10 mm from the annular plane) with bulky calcification on CT planning, posing an unacceptable risk of coronary ostial occlusion during deployment.

Severe Unfavorable Peripheral Vascular Anatomy: Severe iliofemoral stenosis, extreme tortuosity, or circumferential calcification that precludes safe insertion of a 14-16 Fr delivery sheath (mandates alternative access or surgical intervention).

TAVI Procedural Approaches and Valve Technologies

The common femoral artery in the groin is accessed percutaneously under ultrasound and fluoroscopic guidance. Accounting for >90-95% of all global TAVI cases, transfemoral delivery is the least invasive approach, performed under local anesthesia with light conscious sedation. Vascular access is secured and subsequently closed using specialized percutaneous suture-mediated or collagen-based vascular closure devices (e.g., ProGlide, ProStyle, or MANTA), enabling ambulation within hours.

Procedural Steps: How TAVI is Performed

Clinical Option	Surgical Invasiveness	Primary Patient Profile	Key Clinical Trade-offs
TAVI / TAVR (This Procedure)	Percutaneous arterial puncture; local anesthesia/sedation; no CPB	Patients ≥75-80 years, or intermediate-to-high surgical risk (STS/EuroSCORE II ≥4%)	Rapid recovery (2-4 days in hospital); avoiding sternotomy; higher risk of conduction disturbances / pacemaker (5-15%)
Surgical Aortic Valve Replacement (SAVR)	Median sternotomy or ministernotomy; cardiopulmonary bypass and cardioplegia arrest	Younger adults (<65-70 years), low surgical risk, bicuspid valves, or multi-valvular disease	Extensive long-term durability data (>20-25 yrs for mechanical); longer recovery (6-8 weeks); sternal healing constraints
Balloon Aortic Valvuloplasty (BAV)	Percutaneous catheter balloon inflation across the valve	Palliative bridging in hemodynamically unstable patients or non-cardiac urgent surgery	Temporary hemodynamic improvement only; high rate of restenosis within 6 to 12 months
Medical Management Only	Non-invasive pharmacotherapy (diuretics, statins, anti-hypertensives)	Asymptomatic mild/moderate AS, or patients with terminal non-cardiac conditions (life expectancy <1 yr)	Symptom mitigation only; does not arrest hemodynamic progression; 50% 2-year mortality in severe symptomatic AS
Permanent Pacemaker Implantation (PPI)	Transvenous cardiac implant under local anesthesia	Post-TAVI patients developing high-grade or complete atrioventricular (AV) block	A potential post-procedural management step for conduction injury, not an alternative therapy for aortic stenosis

Clinical Parameter	Before TAVI (Severe Aortic Stenosis)	After Successful TAVI Implantation
Aortic Valve Area (AVA)	Severely narrowed (<1.0 cm²; often <0.7 cm²)	Expanded to normal functional orifice area (1.6 to 2.2 cm²)
Mean Transvalvular Gradient	Markedly elevated (>40 to 80 mmHg)	Immediately normalized (<10 to 15 mmHg)
Left Ventricular Afterload	Severe systolic wall stress, concentric hypertrophy	Instant afterload relief; initiates regression of myocardial hypertrophy
Functional Status & Dyspnea	NYHA Class III-IV: Severe dyspnea on minimal exertion	NYHA Class I-II: Rapid symptomatic relief within 48 to 72 hours
Post-Procedure Pharmacotherapy	Carefully restricted heart failure regimens	Single antiplatelet therapy (lifelong aspirin) unless anticoagulation indicated for AF

Step 1
Step 1
Arterial Access and Pre-Closure
Under ultrasound guidance, micropuncture access is achieved in the common femoral artery. Percutaneous suture-mediated closure devices (e.g., Perclose ProGlide) are deployed across the arteriotomy without tying to facilitate subsequent vessel closure. A large-bore expandable delivery sheath (14 to 16 French) is then advanced into the artery.
Step 2
Step 2
Retrograde Crossing and Wire Placement
A specialized steerable catheter and straight-tip hydrophilic wire are navigated retrogradely across the aortic arch and negotiated through the stenotic, calcified aortic valve into the left ventricle. The wire is exchanged for a pre-shaped, stiff guide wire anchored safely in the left ventricular apex.
Systemic anticoagulation is maintained with intravenous unfractionated heparin to achieve an Activated Clotting Time (ACT) >250-300 seconds.
Step 3
Step 3
Balloon Aortic Valvuloplasty (Optional Pre-Dilatation)
In valves exhibiting heavy, asymmetric calcification, an undersized valvuloplasty balloon is positioned across the native valve and inflated under brief rapid ventricular pacing (180-200 bpm) to crack calcific nodules and facilitate passage of the prosthetic delivery system.
Step 4
Step 4
Prosthesis Tracking and Annular Alignment
The crimped transcatheter valve system is advanced over the stiff wire through the aorta and positioned across the native aortic annulus. High-resolution fluoroscopy aligned precisely to the coplanar or cusp-overlap angiographic view confirms accurate height and depth of insertion relative to the annular plane.
Step 5
Step 5
Controlled Valve Deployment and Rapid Pacing
Depending on the chosen platform, the valve is deployed: Balloon-expandable valves are expanded in seconds under rapid ventricular pacing to ensure zero forward cardiac motion; Self-expanding valves are unsheathed slowly under precise fluoroscopic control, allowing fine-tuning of depth before final release.
The native calcified cusps are permanently pinned back against the aortic wall, functioning as an anchor for the newly expanded stent frame.
Step 6
Step 6
Hemodynamic Assessment and Access Hemostasis
Immediate post-deployment aortography and hemodynamic pressure measurements verify gradient reduction and rule out significant paravalvular regurgitant leaks or coronary compromise. The delivery sheath is withdrawn, and the femoral arteriotomy is cinched tight using the pre-deployed vascular closure devices to achieve immediate hemostasis without open surgical cutdown.

Procedural Risks, Complications, and Safety Profile

TAVI carries a favorable safety profile compared to surgical intervention in high-risk patients. Nonetheless, because it is an endovascular intervention in elderly patients with complex vascular anatomy, recognized complications can occur:

Common / Anticipated Effects: Local groin bruising, minor hematoma at the puncture site, transient blood pressure fluctuations, and mild post-procedural fatigue.

Cardiac Conduction Disturbances & Pacemaker Dependency: Because the aortic annulus lies in immediate anatomical proximity to the atrioventricular (AV) node and the left bundle branch (bundle of His), radial stent expansion can produce mechanical compression or ischemia of the conduction system. New-onset high-grade AV block or complete heart block occurs in approximately 5-15% of patients (higher with deep implantation and self-expanding valves), requiring a permanent pacemaker (PPM) prior to discharge.

Vascular Access Complications: Iliofemoral dissection, arterial rupture, pseudoaneurysm, or retroperitoneal hematoma (occurs in 2-4% of patients), managed with covered endovascular stents or surgical repair.

Cerebrovascular Events (Stroke / TIA): Periprocedural ischemic stroke occurs in 1-3% of patients, primarily caused by micro-embolization of calcific debris or atheroma from the aorta during wire and catheter manipulation. Cerebral embolic protection devices (e.g., filter baskets in the carotid arteries) may be used in high-risk anatomies to capture debris.

Paravalvular Regurgitant Leak (PVL): Incomplete sealing between the transcatheter stent frame and the calcified annular ring can leave minor residual backward leaks. Modern valves feature outer pericardial sealing skirts that have reduced moderate-to-severe PVL to <1-2%.

Rare and Critical Adverse Events: Acute coronary ostial obstruction (<0.5%), aortic annular rupture (<0.5%), cardiac tamponade, need for emergency open conversion (<1%), and 30-day procedural mortality (<1-2% in low/intermediate-risk patients).

Frequently Asked Questions

Recovery Phase	Clinical Care and Patient Progress
First 4 to 6 Hours (CCU/Post-Cath Recovery)	Flat bed rest with the punctured leg kept straight to ensure femoral closure hemostasis; continuous ECG telemetry to monitor for new conduction blocks; early oral fluids.
Day 1 (24 Hours Post-Procedure)	Removal of arterial lines and urinary catheters; assisted out-of-bed ambulation and sitting in a chair; light solid oral diet; transition from CCU to a step-down ward.
Days 2 to 4 (Discharge Planning)	Independent ward walking; transthoracic echocardiography to document post-implant valve area and exclude paravalvular leak; 24-48 hour continuous ECG rhythm assessment; discharge home.
Weeks 1 to 2 (Home Convalescence)	Avoid lifting heavy weights (>4-5 kg) to protect the femoral puncture site; light daily walking; complete healing of the groin puncture wound.
Weeks 4 and Beyond	Return to regular non-strenuous daily activities and driving (if cleared by the cardiologist); outpatient baseline echocardiogram and Heart Team follow-up review.

What is TAVI (TAVR) and how does it work?

TAVI (Transcatheter Aortic Valve Implantation) is a minimally invasive percutaneous procedure to treat severe aortic stenosis. A collapsed artificial tissue valve is delivered on a catheter through a blood vessel in the groin (femoral artery) and expanded inside the diseased, calcified aortic valve, restoring normal blood flow without opening the chest or stopping the heart.

Who is an ideal candidate for TAVI?

TAVI is recommended for patients with severe symptomatic aortic stenosis who are aged 75 years or older, or those of any age who have elevated surgical risk due to prior heart surgery, porcelain aorta, frailty, lung disease, or kidney impairment. Suitability requires confirmation of favorable femoral artery diameter and aortic root anatomy on a dedicated ECG-gated CT scan.

How is TAVI different from open-heart surgical valve replacement (SAVR)?

SAVR requires a median sternotomy (cutting open the breastbone), stopping the heart with a heart-lung machine, surgical excision of the old valve, and a 6-to-8-week recovery. TAVI is performed through a pinhole in the groin, usually with mild conscious sedation, keeps the native valve pinned aside, and allows patients to walk the next day and return home in 2 to 4 days.

Is TAVI painful or done under general anesthesia?

TAVI is generally painless once local numbing medication is applied to the groin. More than 80% of transfemoral TAVI cases are performed under conscious sedation (monitored anesthesia care), meaning you remain relaxed and breathing on your own without a general anesthesia breathing tube.

Why do some patients need a permanent pacemaker after TAVI?

The heart's electrical conduction system (the AV node and bundle of His) runs directly underneath the aortic valve annulus. When the new stent frame expands against calcified leaflets, it can compress these electrical pathways, causing heart block. Approximately 5-15% of patients develop high-grade conduction delays requiring a permanent pacemaker.

How long does a transcatheter aortic valve last?

Long-term data from landmark clinical trials indicate that TAVI tissue valves exhibit durability comparable to surgical bioprosthetic valves, with low rates of structural valve deterioration at 5 to 10 years. If a TAVI valve degenerates in the distant future, another catheter valve can often be placed inside it (TAVI-in-TAVI).

What medications are required after TAVI?

Most patients without an existing indication for oral anticoagulation are prescribed Single Antiplatelet Therapy (lifelong low-dose aspirin). Routine lifelong warfarin is NOT required for TAVI valves. If you have atrial fibrillation, your cardiologist will maintain you on an oral anticoagulant alone.

Why are prophylactic antibiotics required for dental visits after TAVI?

A transcatheter valve is a prosthetic device that can harbor bacteria circulating in the bloodstream during invasive dental procedures. Taking a single dose of prophylactic antibiotics (such as amoxicillin) 30 to 60 minutes before dental cleanings or extractions prevents infective endocarditis.

How soon can I resume normal activities and driving?

Patients can walk within 12 to 24 hours and typically resume light daily activities within 1 to 2 weeks. Strenuous physical exertion and heavy lifting (>4-5 kg) should be avoided for 2 to 4 weeks to allow complete healing of the femoral puncture site. Driving is generally cleared after 2 to 4 weeks upon physician review.

Does health insurance in India cover TAVI?

Many private insurance companies and corporate TPAs in India cover TAVI when pre-authorized under strict medical necessity criteria (e.g., documented high surgical risk or elderly age). Government and central schemes like CGHS and EHS have approved package limits for TAVI in empanelled hospitals.

TAVI (Transcatheter Aortic Valve Implantation): Indications, Procedure, Recovery, and Cost in India

TAVI (Transcatheter Aortic Valve Implantation): Indications, Procedure, Recovery, and Cost in India

Quick Clinical Summary

Free Second Opinion

Clinical Signs and Symptoms of Severe Aortic Stenosis

Etiology and Pathophysiology of Aortic Stenosis

Etiology and Pathophysiology of Aortic Stenosis

Hemodynamic Impact: Ventricular Hypertrophy and Heart Failure

What is TAVI / TAVR (Transcatheter Aortic Valve Implantation)?

Clinical Indications and Patient Selection for TAVI

Clinical Contraindications and Deferral Criteria

Risks of Delaying Valve Intervention in Aortic Stenosis

Know Your Insurance Benefits

TAVI Procedural Approaches and Valve Technologies

Comparison of Aortic Stenosis Treatment Modalities

Preoperative Workup and Clinical Planning

Day of the Procedure: Intraprocedural Pathway

Hemodynamic and Clinical Comparison: Before vs. After TAVI

Procedural Steps: How TAVI is Performed

Arterial Access and Pre-Closure

Retrograde Crossing and Wire Placement

Balloon Aortic Valvuloplasty (Optional Pre-Dilatation)

Prosthesis Tracking and Annular Alignment

Controlled Valve Deployment and Rapid Pacing

Hemodynamic Assessment and Access Hemostasis

Expert Guidance, Every Step of the Way

Procedural Risks, Complications, and Safety Profile

Post-TAVI Recovery and Ambulation Timeline

Post-Procedure Surveillance and Follow-Up Protocols

Warning Signs: When to Seek Immediate Medical Attention

Clinical Guidelines and Landmark Trial Evidence

Key Questions to Ask Your Structural Heart Team

Frequently Asked Questions

Too Many Doctors. Too Many Searches. Too Much Confusion.

Choosing the Right Structural Heart Center and Specialists

Mohd Ateequrrahman

Check if your TAVI / TAVR (Transcatheter Aortic Valve Implantation / Replacement) is covered — before you decide.

Find a Surgeon You Can Trust

We don't disappear after your TAVI / TAVR (Transcatheter Aortic Valve Implantation / Replacement).

Related Valvular and Structural Heart Conditions

Related Interventional and Surgical Procedures

Clinical Specialty

Talk to our care team

Expert Second Opinion

Mohd Ateequrrahman